Rothschild, one of the volume’s editors, discusses the HPA axis in relation to psychiatric illness. Curiously, the bulk of his chapter covers only the dexamethasone suppression test. This test is not in widespread use currently, although a number of investigators, including me, believe it has been shelved prematurely. The only other topic in Rothschild’s chapter is a short discussion of the treatment of depression with antiglucocorticoid drugs, e.g., cortisol synthesis inhibitors. These drugs have not been incorporated into clinical practice because they are only modestly effective, and generally only in the 30%–50% of depressed patients who have elevated HPA activity. Rothschild mentions the progesterone (and, at high concentrations, glucocorticoid) receptor antagonist mifepristone for treating psychotic depression. Mifepristone currently is approved for terminating early pregnancy. Notwithstanding the lack of confirmatory double-blind studies of its antidepressant efficacy, its limitation in treating depressed women of childbearing age is obvious, but this limitation is not discussed. Also troublesome is Rothschild’s undisclosed financial interest in Corcept Therapeutics, which is attempting to establish mifepristone as an antidepressant. As one of the editors of this volume, Rothschild had the opportunity to set a standard for disclosing financial conflicts of interest in book chapters, but he did not do so.